Our research

Our mission is to accelerate the search for a cure for motor neuron disease. Our research programme takes what we learn from our patients into the laboratory, using that knowledge to build possible treatments, then tests those possible treatments in clinical trials. Our programme of work has already started and is growing.

The three pillars of UK MND RI research

Understanding the MND patient and disease process

Understanding the patient and disease process

We have three programmes looking to understand MND in detail; MND Register and biobank, Telehealth in Medicine (TiM) – Research, and Trajectories of Outcomes in Neurological Conditions (TONiC).

Identifying possible drugs to treat MND

Identifying possible drugs to treat MND

We have two programmes developing new drugs, and these work in tandem with other initiatives nationally and internationally.

Testing new treatments in clinical trials

Testing new treatments in clinical trials

Testing new treatments in clinical trials; EXPERTS-ALS, MND-SMART, and TRICALS.

Taking part in MND clinical trials

The UK MND Clinical Studies Group is the clinical & healthcare research arm of the UK MND RI, a national group bringing together clinical researchers from across the UK, along with representatives from patient advocacy groups, to support the development and delivery of MND research projects. If you are interested in taking part in a clinical trial, please visit the CSG website.

The UK MND RI is proud to be collaborating with the following initiatives:

DPUK/HDRUK Data Platform Partnership Programme

The MND data Platform is a new partnership programme, jointly led by Health Data Research UK (HDR UK) and Dementias Platform UK (DPUK), in partnership with the UK MND Research Institute (UK MND RI) to convene and deliver data infrastructure and services, specifically designed to accelerate MND research.

MNDF Advancing Treatments Award and Discovery Network

MNDF Advancing Treatments Award and Discovery Network

The UK MND RI are working together with the My Name’5 Doddie Foundation on two new funding initiatives in MND Translational research. Through the Discovery Network, researchers will identify new therapeutic targets, and the Advancing Treatments Award will help to translate potential targets into new treatments.

Challenge Works Longitude prize on ALS

Challenge Works believe a Challenge Prize can drive developments in ALS treatment and raise awareness of this life-limiting disease. They are exploring two prize designs; (i) a prize to uncover subtypes of ALS through big data and AI to drive a personalised medicine approach to novel treatment development and clinical care, and (ii) a prize to develop multimodal medicines to drive the development of treatments to tackle the multifaceted nature of ALS.

DPUK MND Accelerator

The MND Translational Accelerator (MNDAcc) is a £6m investment by the Medical Research Council and the National Institute for Health and Care Research to quicken the development of treatments for MND, and the related condition of Frontotemporal dementia (FTD). MNDAcc is part of a national drive to translate new discoveries into treatments, providing infrastructure, facilities, services, and funding for high quality in-human research.

LifeArc Translational Challenge in MND

The LifeArc Motor Neuron Disease Translational Challenge is the new multi-million-pound programme to accelerate scientific innovation for people living with MND. LifeArc are partnering with patients, academics, charities, healthcare professionals and industry to fast-track scientific discoveries into new clinical solutions to transform how MND is detected, treated, and managed.

MRC Researching MND Highlight Notice

MRC in partnership with NIHR are seeking to encourage high-quality funding applications in MND to any of our research board or panel grant or fellowship opportunities. Through this highlight notice, applicants are invited to submit innovative research proposals to MRC that aim to: (i) improve the mechanistic understanding of MND, including identification and validation of new biomarkers, and (ii) investigate potential new therapeutic avenues.